All In Biotech

Drug Trial Radar · NCT00139815

Michelangelo - Oasis 5

An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes

Last checked: Nov 19, 2026Latest source record: Sep 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 20,078 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20,078

Actual

Start

Apr 2003

Primary completion

Dec 2005

Study completion Dec 2005

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
University of Chicago; Organon; Sanofi; Duke University
First posted
Aug 31, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Objectives PRIMARY OBJECTIVE: To evaluate whether fondaparinux is at least as effective as or superior to enoxaparin in preventing death, myocardial infarction or refactory ischemia up to Day 9 in the acute treatment of patients with unstable angina/non ST-segment elevation myocardial infarction concurrently managed with standard medical therapy. SECONDARY OBJECTIVE: If non inferiority of fondaparinux is established on initial statistical analysis in a second step, superiority of fondaparinux to enoxaparin will be evaluated statistically. * To determine whether fondaparinux is superior to enoxaparin in reducing death or MI at Day 9 * To determine whether fondaparinux is superior to enoxaparin in reducing major bleeding events up to Day 9 * To determine whether the relative effect on the primary end point of fondaparinux versus enoxaparin is sustained at Day 14, Day 30, Day 90 and Day 180 Study Drug: Patients will be randomized to receive either: * Fondaparinux 2.5 mg once and placebo-enoxaparin twice daily by subcutaneous injection or * Enoxaparin (1mg/kg) twice and fondaparinux-placebo once daily by subcutaneous injection Duration of Therapy: * Fondaparinux 2.5mg daily for 8 days or hospital discharge (whichever is earlier) * Enoxaparin 1mg/kg b.i.d. x 2-8 days or until clinically stable. * Patients should receive an ASA and all other standard medical therapies. Substudy: * A substudy comparing routine early coronary angiography immediately or as soon as possible (but no later than 24 hours after randomization) and intervention versus delayed (\>48 hrs) coronary angiography and intervention. Primary Outcome: The first occurence of any component of the following composite up to Day 9: * Death * Myocardial Infarction * Refractory Ischemia

Conditions

  • Thromboembolism

Interventions

  • FondaparinuxDrug

    fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable

  • enoxaparinDrug

    enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. death, myocardial infarction or refractoryTime frame: up to and including Day 9
  2. major bleedingTime frame: Up to Day 9

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.